Atopic dermatitis is one of the most common chronic inflammatory skin diseases in America, especially among African American and Asian American patients. However, several factors contribute to the misdiagnosis and underdiagnosis of atopic dermatitis among these patients, which is why Dr. Vivian Shi is here to shed light on those factors as well as the key signs and symptoms of atopic dermatitis in patients with skin of color.

VERSION 1.0 | NOVEMBER 2021 | ABBV-US-00686-MC

Atopic dermatitis affects patients’ lives in a way that goes beyond just visible symptoms. In fact, many patients with atopic dermatitis also suffer from anxiety, depression, and attention deficit hyperactivity disorder. That’s why Dr. Vivian Shi is here to review available tools that can help us assess the severity of the visible and invisible impacts of atopic dermatitis.

VERSION 2.0 | DECEMBER 2021 | ABBV-US-00687-MC

Acute hepatic porphyria (AHP) is a rare genetic condition characterized by severe, diffuse abdominal pain and a broad range of seemingly unrelated symptoms. AHP presents differently in each patient, with symptoms that mirror those of more common conditions, making it difficult to diagnose. Although AHP can be misleading, it can be easy to detect once you know what to look for. Joining Dr. Charles Turck to discuss AHP signs and symptoms and when a doctor should consider AHP in a patient is porphyria expert Dr. Manish Thapar, gastroenterologist and associate professor of medicine in Philadelphia.

©2021 Alnylam Pharmaceuticals, Inc. All Rights Reserved. AS1-USA-01069

Mycoplasma genitalium (M. gen) is an STI that shares similar health consequences to chlamydia and gonorrhea. Further complicating this health threat is the fact that there’s been little guidance on how to manage this new pathogen until recently when the 2021 STI Treatment Guidelines were released. Joining Dr. Jennifer Caudle to talk about M. gen and why the guidelines recommend the use of nucleic acid amplification tests for the diagnosis of this pathogen is Dr. Erik Munson, an Assistant Professor of Clinical Laboratory Science at Marquette University.

Despite their crucial role in preventing seasonal influenza, traditional influenza vaccines may not be providing as much protection as we thought, leading researchers to take a look at different methods of vaccine production, specifically cell-based flu vaccine production. Here with Dr. Charles Turck to discuss influenza prevention and the latest evidence supporting a cell-based vaccine option is Dr. Mark Blatter.

USA-QIVc-21-0146 November 2021

Plaque psoriasis is canonically characterized by red, scaly, well demarcated plaques; however, the impact of this chronic systemic disease cannot be fully understood by the extent of skin involvement alone. Moderate psoriasis can have a large impact on patients due to factors such as involvement of special areas (such as the scalp) and persistent itching. Reaching a better understanding of these patients requires looking beyond skin involvement, assessing all aspects of disease, and considering patient perspectives.

Ms. Melodie Young, a Nurse Practitioner specialist of dermatology, joins Dr. Jennifer Caudle to give us deeper insight into this systemic disease, the potential impact on patients with moderate disease, and important aspects of psoriasis to consider in disease assessment.

USA-407-81472

Multiple sclerosis is a chronic inflammatory and neurodegenerative disease with a highly variable clinical course.1,2 Most patients who have relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course (SPMS).3 Patients with SPMS may live with significant impairment in physical and cognitive functions.4 Early identification of disease progression is important.2

Join Dr. Barry Singer from the MS Center for Innovations in Care at the Missouri Baptist Medical Center in St Louis, Missouri as well as Dr. Ann Bass from the Neurology Center of San Antonio in San Antonio, Texas as they share their real-world clinical perspectives on the management of patients with more progressed RMS, including those with aSPMS, and MAYZENT as a treatment option. Together, they will explore the following decision points:

• How to actively identify first signs of RMS progression
• A therapy for progressing RMS, including active SPMS
• What to consider when getting patients started on MAYZENT, a disease-modifying treatment

Despite significant advancements in therapeutics, the oncology community has not yet been able to declare victory in the “war on cancer.” In fact, about 40 percent of Americans receive a cancer diagnosis in their lifetime, amounting to over 600,000 American deaths on average every year or nearly 1,700 loved ones a day. But could hope be on the horizon thanks to technological developments like multi-cancer early detection (MCED)? Find out with Dr. Paul Doghramji and Dr. Joshua Ofman, a public health services researcher as well as the Chief Medical Officer and Head of External Affairs at GRAIL.

Our understanding of immunoglobins’ role in multiple sclerosis (MS) has evolved over the years. Joining Dr. Jason Freeman to share what we currently know about immunoglobins and immunology considerations for MS therapies and patient case scenarios is Dr. Scott Zamvil, Professor of Neurology and Faculty Member in the Program in Immunology at the University of California, San Francisco.

9/21 152858

Have you considered POMALYST® (pomalidomide) containing regimens for your appropriate patients with relapsed/refractory multiple myeloma who have received lenalidomide and a proteasome inhibitor? Tune in to hear key findings from clinical trials, including safety and efficacy data, and other important information regarding these treatment regimens.

Please see full Prescribing Information for POMALYST, including Boxed WARNINGS, and full Prescribing Information for EMPLICITI.

POMALYST and EMPLICITI Indications

POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

EMPLICITI® (elotuzumab) is indicated in combination with POMALYST and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

POMALYST + dexamethasone + daratumumab Indication

POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Information about POMALYST + dexamethasone + …